Worse prognosis in women, compared with men, after thrombolysis: An individual patient data pooling study of Asian acute stroke registries.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
10 2021
Historique:
pubmed: 9 7 2020
medline: 12 11 2021
entrez: 9 7 2020
Statut: ppublish

Résumé

To examine sex differences in disease profiles and short-term outcomes after acute ischemic stroke treated with recombinant tissue plasminogen activator. Eight national and regional stroke registries contributed individual participant data from mainland China, Japan, Philippines, Singapore, South Korea and Taiwan in 2005-2018. The primary outcome was ordinal-modified Rankin scale at 90 days. Key safety outcome was symptomatic intracerebral hemorrhage (sICH). Of 4453 patients included in the analyses, 1692 (36.3%) were women who were older, more likely to have a more severe neurological deficit, history of hypertension and atrial fibrillation, and a cardioembolic stroke compared to men. Women were more likely than men to have unfavorable shift of modified Rankin scale (fully adjusted odds ratio) (women vs. men) 1.14, 95% confidence interval 1.02-1.28). There was no significant sex difference for death 1.05 (0.84-1.31) or sICH (1.17, 0.89-1.54). Women were more likely to have unfavorable functional outcome with increasing age (P = 0.022 for interaction). In the age groups 70-80 and ≥80 years, women had a worse functional outcome compared to men (1.22, 1.02-1.47 and 1.43, and 1.06-1.92, respectively). In this pooled data from Asian acute stroke registries, women had poorer prognosis than men after receiving recombinant tissue plasminogen activator for acute ischemic stroke, which worsened with age. Women older than 70 appear to have a worse outcome than men which could be explained by greater stroke severity, more AF, and cardioembolic stroke.

Sections du résumé

BACKGROUND AND PURPOSE
To examine sex differences in disease profiles and short-term outcomes after acute ischemic stroke treated with recombinant tissue plasminogen activator.
METHODS
Eight national and regional stroke registries contributed individual participant data from mainland China, Japan, Philippines, Singapore, South Korea and Taiwan in 2005-2018. The primary outcome was ordinal-modified Rankin scale at 90 days. Key safety outcome was symptomatic intracerebral hemorrhage (sICH).
RESULTS
Of 4453 patients included in the analyses, 1692 (36.3%) were women who were older, more likely to have a more severe neurological deficit, history of hypertension and atrial fibrillation, and a cardioembolic stroke compared to men. Women were more likely than men to have unfavorable shift of modified Rankin scale (fully adjusted odds ratio) (women vs. men) 1.14, 95% confidence interval 1.02-1.28). There was no significant sex difference for death 1.05 (0.84-1.31) or sICH (1.17, 0.89-1.54). Women were more likely to have unfavorable functional outcome with increasing age (P = 0.022 for interaction). In the age groups 70-80 and ≥80 years, women had a worse functional outcome compared to men (1.22, 1.02-1.47 and 1.43, and 1.06-1.92, respectively).
CONCLUSION
In this pooled data from Asian acute stroke registries, women had poorer prognosis than men after receiving recombinant tissue plasminogen activator for acute ischemic stroke, which worsened with age. Women older than 70 appear to have a worse outcome than men which could be explained by greater stroke severity, more AF, and cardioembolic stroke.

Identifiants

pubmed: 32638639
doi: 10.1177/1747493020938307
doi:

Substances chimiques

Fibrinolytic Agents 0
Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

784-791

Auteurs

Xia Wang (X)

The George Institute for Global Health, University of New South Wales, NSW, Australia.

Cheryl Carcel (C)

The George Institute for Global Health, University of New South Wales, NSW, Australia.
Sydney School of Public Health, University of Sydney, NSW, Australia.

Ruigang Wang (R)

North China University of Science and Technology Affiliated Hospital, HeBei Province, Tangshan, China.

Jingwei Li (J)

Department of Cardiology, People's Liberation Army General Hospital, Beijing, China.
Department of Cardiology, Xinqiao Hospital, Third Military Medical University, Chongqing, China.

Hee-Joon Bae (HJ)

Department of Neurology and Cerebrovascular Center, Seoul National University, Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea.

Yilong Wang (Y)

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Anxin Wang (A)

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Yongjun Wang (Y)

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Kazunori Toyoda (K)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.

Yi Sui (Y)

Shenyang First People's Hospital, Shenyang Medical College Affiliated Shenyang Brain Hospital, Shenyang Brain Institute, Shenyang Clinical Research Center for Neurological Disorders, Shenyang, China.

Tsong-Hai Lee (TH)

Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and College of Medicine, Chang Gung University, Taoyuan.

Jose C Navarro (JC)

Stroke Services, Department of Neurology, Jose R. Reyes Memorial Medical Center, Manila, Philippines.

Mu-Chien Sun (MC)

Department of Neurology, Changhua Christian Hospital, Changhua.

Craig S Anderson (CS)

The George Institute for Global Health, University of New South Wales, NSW, Australia.
The George Institute China at Peking University Health Science Center, Beijing, PR China.
Neurology Department, Royal Prince Alfred Hospital, Sydney Health Partners, Sydney, NSW, Australia.
Health Heart Research Center, Beijing, China.

Vijay Sharma (V)

Division of Neurology, National University Hospital, Singapore.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Else C Sandset (EC)

Department of Neurology, Oslo University Hospital, Oslo, Norway.
Norwegian Air Ambulance Foundation, Oslo, Norway.

Mark Woodward (M)

The George Institute for Global Health, University of New South Wales, NSW, Australia.
The George Institute for Global Health, University of Oxford, Oxford, UK.
Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH